Genetic variation in neuroendocrine genes associates with somatic symptoms in the general population: Results from the EPIFUND study  by Holliday, Kate L. et al.
earch 68 (2010) 469–474Journal of Psychosomatic ResGenetic variation in neuroendocrine genes associates with somatic
symptoms in the general population: Results from the EPIFUND study
Kate L. Hollidaya,⁎,1, Gary J. Macfarlaneb, Barbara I. Nicholla, Francis Creedc,
Wendy Thomsona,2, John McBetha,2
aarc Epidemiology Unit, University of Manchester, Manchester, UK
bAberdeen Pain Research Collaboration (Epidemiology Group), University of Aberdeen, UK
cPsychiatry Research Group, School of Medicine, University of Manchester, Manchester, UK
Received 16 November 2009; received in revised form 26 January 2010; accepted 28 January 2010AbstractObjective: Functional somatic syndromes commonly occur
together, share a genetic component and are associated with
numerous somatic symptoms. This study aimed to determine if
genetic variation in two neuroendocrine systems, the serotoniner-
gic system and the hypothalamic-pituitary-adrenal (HPA) axis, was
associated with the number of reported somatic symptoms.
Methods: This population-based cohort study (Epidemiology of
Functional Disorders) recruited participants from three primary
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Symptoms Checklist, Hospital Anxiety and Depression scales, and
body manikins, respectively, via a postal questionnaire. Tag Single
Nucleotide Polymorphisms (SNPs) (r2N0.8) were selected for
serotoninergic system genes (TPH2, SLC6A4 and HTR2A) and
HPA axis genes (CRH, CRHR1, CRHBP, MC2R, POMC, NR3C1,
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Open access under CC BY-NC-ND license. Negative binomial regression was used to test for association
between SNPs and the number of somatic symptoms. Stepwise-
regression was used to identify independent effects and adjust-
ments were made for anxiety, depression, and pain. Results: A
total of 967 subjects were successfully genotyped for 143 (87%)
SNPs. Multiple SNP associations with the number of somatic
symptoms were observed in HTR2A and SERPINA6 as well as two
SNPs in TPH2. Stepwise regression identified two effects in
HTR2A and a single effect in TPH2 which were independent of
anxiety, depression, and pain. A single effect was also identified in
SERPINA6 but was no longer significant when adjusted for pain.
Conclusion: This study finds association of SNPs in HTR2A,
SERPINA6, and TPH2 with somatic symptoms implicating them as
potentially important in the shared genetic component to functional
somatic syndromes, although replication is required.
© 2010 Elsevier Inc. Open access under CC BY-NC-ND license. Keywords: (max 6); Somatisation; Polymorphism; Genetics; Serotonin; HPAIntroduction
Functional somatic syndromes, which are characterized
by medically unexplained symptoms, share common fea-
tures including overlapping symptoms, a female preponder-
ance, and frequent comorbid depression and anxiety. These
syndromes, which include, among others, fibromyalgia (FM)[chronic widespread pain (CWP)], chronic fatigue syndrome
(CFS), and irritable bowel syndrome (IBS), also have
distinct differences and whether they should be considered
as discrete entities has been widely debated [1].
Familial aggregation of FM has been repeatedly demon-
strated [2–4], and a twin study of CWP estimated heritability
to be approximately 50% [5]. Twin studies have also
reported a genetic component to CFS [6,7] and IBS [8,9].
Not all twin studies of IBS, however, have reported a genetic
component [10,11], and others have found that the observed
genetic component is explained by a genetic influence on
associated psychiatric disorder or a tendency to report
multiple bodily symptoms [12,13].
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common genetic risk factors, Kato et al. carried out a
population-based twin study of functional (CWP, CFS, IBS,
and recurrent headache) and psychiatric disorders (major
depression and generalized anxiety disorder) [14]. Although a
specific genetic component to each functional syndrome was
observed, the findings also implied that there are genetic
factors influencing pain sensitization and psychiatric disorders
which are shared across these functional somatic syndromes.
Reporting of somatic symptoms is common across these
frequently co-occurring syndromes [15] and somatic symp-
toms have been shown to predict new-onset IBS [16] and
CWP [17] independently of other psychosocial factors.
Therefore, when looking for genetic risk factors for these
functional somatic syndromes, somatic symptoms may act as
a suitable marker. Alternatively, a genetic predisposition to
somatization itself, which has been reported [13,18], may be
an important factor in whether or not individuals develop a
functional syndrome/s.
We have previously conducted candidate gene studies of
the primary stress response system (hypothalamic-pituitary-
adrenal axis (HPA) and the serotoninergic system with
musculoskeletal pain due to the altered functioning of these
systems in FM [19–22]. We reported evidence of genetic
association in the serotonin receptor 2A gene (HTR2A), the
serotonin biosynthesis gene (TPH2) [23], and the corticoste-
roid binding globulin gene (SERPINA6) [24] with CWP and
the extent of pain in a population-based cohort, EPIFUND.
Both of these neuroendocrine systems may also be important
in somatization. HPA axis function has been investigated in
IBS and CFS; however, the results are inconclusive [25]. The
mechanism is unknown, but selective serotonin reuptake
inhibitors appear to be effective in somatization [26,27].
Consequently, the aim of this study was to determine if
genetic variation in these neuroendocrine pathways is
associated with somatic symptoms in the general population.Methods
Subjects
Subjects included in this analysis were participants in
EPIFUND (Epidemiology of Functional Disorders), a
prospective population-based cohort study with data collect-
ed at 3 time-points over a 4-year period. Subjects aged 25–
65 years old were recruited from three primary care registers
in the North-West of England.
Ascertainment of somatic symptoms
The Somatic Symptoms Checklist, a seven-item validated
screening test for life-time somatization [28], was used to
determine a score for the number of somatic symptoms in
each subject at baseline via a postal questionnaire. The score
was determined for each individual using 5-items, troubled
breathing, frequent pain in fingers or toes, frequent vomiting(when not pregnant), loss of voice, and loss of memory
giving a total somatic symptoms score ranging from 0–5.
Two further items were excluded from the somatic
symptoms score. Frequent trouble with menstrual cramps
was excluded so that scores were comparable between
genders and the item on difficulty swallowing was excluded
due to a high proportion of missing answers.
Ascertainment of anxiety, depression and pain
Anxiety and depression were assessed at baseline using
the Hospital Anxiety and Depression (HAD) scale [29]. The
HAD questionnaire contains seven items on anxiety and
seven items on depression in the last week which are
answered on a four-point Likert scale (0–3) with total scores
ranging from 0 to 21. Higher scores indicate an increased
likelihood of having an anxiety or depressive disorder.
Subjects completed a detailed pain questionnaire at all
three time-points which asked whether they had experienced
aches or pains lasting for one day or longer in the past month.
The location of any pain reported was then shaded on body
manikins (right and left sides, front and back). A coding
schedule [30], which divides the body into 29 sites was used
to determine the total number of pain sites [from 0 (no pain)
to 29 (pain in all sites)] at each time-point. Each individual's
highest number of pain sites reported at any of the three time-
points was considered as their maximum number of pain
sites (i.e., 0–29 painful sites).
Genetic analysis
DNA samples, using buccal swab sampling, were obtained
with informed consent from subjects participating in the
second follow up with informed consent. Pair-wise tagging
single nucleotide polymorphisms (SNPs) (r2≥0.8) with a
minor allele frequency (MAF) greater than 5% were selected
for HPA axis genes (CRH, CRHBP, CRHR1, POMC, MC2R,
NR3C1, and SERPINA6) and serotoninergic system genes
(HTR2A, SLC6A4, and TPH2) and their 10-kb flanking regions
using Tagger and HapMap CEPH data [31] implemented in
Haploview version 3.32 [32]. Genotyping of all SNPs was
carried out using SequenomMassARRAY technology follow-
ing the manufacturer's instructions (www.sequenom.com).
Quality control thresholds for sample and assay quality
were set to 90%. Deviation from Hardy-Weinberg Equilib-
rium (HWE) was tested in all samples passing QC, with SNPs
showing a significant deviation (P≤.01) being excluded from
the analysis. Allele frequencies were also checked for
consistency with HapMap frequencies. Linkage disequilib-
rium (LD) between SNPs was examined by pair-wise
comparisons of r2 and D′ using Haploview version 3.32 [32].
Statistical analysis
The distribution of the somatic symptoms scores is
positively skewed, and the data is over-dispersed. Therefore,
Table 1
Characteristics of the study population
Somatic Symptoms Score
P0 1 2 3 4 5 Total
n (%) 513 280 125 35 11 3 967 –
% female 50.3 67.1 66.4 74.3 72.7 100 58.5 b.001
Age, mean (SD) 49.4 (10.2) 49.3 (10.1) 49.8 (10.9) 50.5 (8.5) 49.8 (9.6) 41.3 (12.2) 49.5 (10.2) .891
HAD anxiety score, median (IQ range) 4 (2–7) 5 (3–8) 7 (4–10) 10 (7–13) 12 (9–13) 17 (10–17) 5 (3–8) b.001
HAD depression score, median (IQ range) 2 (1–4) 3 (1–6) 4 (2–7) 7 (3–10) 10 (5–12) 8 (6–14) 3 (1–5) b.001
Max number of pain sites, median (IQ range) 4 (1–7) 6 (3–10) 8 (4–13) 13 (8–19) 21 (12–23) 19 (17–28) 5 (2–9) b.001
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association between SNPs and the somatic symptoms score
using an additive model. Results are reported as the
proportional change in somatic symptoms score with 95%
confidence intervals (95% CI) for each copy of the minor
allele. Where multiple significant SNP associations were
observed in the same gene, forward stepwise regression was
used to determine independent effects. The results were
adjusted for HAD anxiety and depression scores and the
maximum number of pain sites. Analysis was conducted in
STATA version 9.2, and p values of less than .05 were
considered statistically significant.Fig. 1. Significant associations with somatic symptoms score in HTR2A.
Proportional change in somatic symptoms score with 95% CI for
significantly associated SNPs in HTR2A. Pair-wise LD [colored by r2
(white=0 black=1] and numbered by D′ (no number where D′=1) between
associated SNPs is shown.Results
Subjects
DNA samples were obtained from 1189 subjects of which
195 (16%) were excluded as they did not meet sample quality
control criteria. Of the remaining 994 subjects, 967 had
complete somatic symptoms data and were included in the
analysis. The distribution of the somatic symptoms score in
these 967 subjects is detailed in Table 1 alongwith information
on demographic characteristics and related comorbidities.
Fifty-three percent of subjects reported 0 somatic symptoms,
29% reported one, and 18% reported two or more. The
percentage of female subjects significantly increased with the
increasing number of somatic symptoms (Pb.001), but age did
not significantly differwith somatic symptoms score (P=.891).
Increasing number of painful sites, HAD depression, and
anxiety scores were significantly associated with increasing
somatic symptoms score (Pb.001 for all comparisons).
Genotyping
Of the 166 Tag SNPs selected, 23 failed genotyping or the
SNP assay quality control threshold. The remaining 143
SNPs were in HWE (PN.01) and had frequencies consistent
with HapMap. Coverage of HapMap SNPs (r2b0.8) within
the genes and their 10-kb flanks ranged from 60% to 100%.
Genetic association analysis
In HTR2A, 10 SNPs spanning 5′ to intron 2 showed
significant associations with the somatic symptoms score(Fig. 1). With the exception of rs2274639, these SNPs are in
a block of relatively high D′, suggesting that limited
recombination has occurred between them. Stepwise regres-
sion analysis showed that the multiple associations were
explained by two effects; each copy of the minor allele of
rs9567746 was associated with a 20% increase in the number
of somatic symptoms [proportional change=1.20 (1.02–
1.41) P=.024] and each copy of the minor allele of
rs2274639 was associated with a decrease in the number of
somatic symptoms [proportional change=0.75 (0.59–0.96)
P=.024]. Both these associations remained significant after
adjusting for HAD depression and anxiety scores and the
maximum number of pain sites; rs9567746 [proportional
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tional change=0.81 (0.67–0.98) P=.03].
In SERPINA6, 7 SNPs spanning the gene showed
evidence of association with somatic symptoms score
(Fig. 2). The SNPs are in a region of high D′, so there has
been limited recombination between these SNPs. Stepwise
regression showed that the associations are explained by a
single effect driven by rs746530, which was associated with
a 19% increase in the number of somatic symptoms for each
copy of the minor allele [proportional change=1.19 (1.05–
1.34) P=.006]. Adjusting for HAD anxiety and depression
scores did not change the result [proportional change=1.16
(1.04–1.30) P=.009]; however, the association was allevi-
ated and no longer significant after adjusting for the
maximum number of pain sites (proportional change=1.09
(0.98–1.21) P=.130).
In TPH2, each copy of the minor allele of rs4565946 and
rs7305115 were associated with a decrease and increase in
the number of somatic symptoms respectively; for
rs4565946 proportional change=0.87 (0.77–0.98) P=.019
and for rs7305115 proportional change=1.14 (1.01–1.28)
P=.029. Moderate LD (r2=0.54) exists between these two
SNPs and stepwise regression found the association
at rs4565946 explained the association at rs7305115.
Adjustment for HAD anxiety and depression scores and
the maximum number of pain sites did not affect thisFig. 2. Significant associations with somatic symptoms score in SERPINA6.
Proportional change in somatic symptoms score with 95% CI for
significantly associated SNPs in SERPINA6. Pair-wise LD [colored by r2
(white=0 black=1) and numbered by D′ (no number where D′=1)] between
associated SNPs is shown.association; rs4565946 proportional change=0.88 (0.79–
0.98) P=.016.
No associations were observed between SNPs in CRH,
CRHBP, CRHR1, POMC, MC2R, NR3C1 and SLC6A4 and
somatic symptoms score.Discussion
To our knowledge this is the first report of a genetic
association study of reporting multiple somatic symptoms.
Associations were observed between SNPs in the serotonin
receptor 2A gene (HTR2A) and the serotonin biosynthesis
gene (tryptophan hydroxylase, TPH2) with the number of
somatic symptoms reported independently of co-morbid
anxiety, depression and pain. The corticosteroid binding
globulin gene, SERPINA6, was also associated with the
number of somatic symptoms but the finding became non-
significant after adjusting for pain.
In this study the minor allele (T) of a synonymous SNP,
rs6313 (T102C), in HTR2A was associated with a decrease
in the number of somatic symptoms. A previous study
reported increased somatization in FM subjects with the TT
genotype compared to CT/CC [33]. The C allele, however,
has been associated with an increased risk of, FM [34], CFS
[35] and Temporomandibular joint disorder [36]. It is
important to note that other studies did not confirm these
findings [33,37] and that all studies had modest sample
sizes. Neither of the SNPs in TPH2, which we have
reported to be associated with the number of somatic
symptoms or the other tag SNPs genotyped have previously
been associated with functional syndromes. However,
Smith et al (2008) found that SNPs in complete LD
(r2=1) with rs7305115, which was associated with the
number of somatic symptoms in this study, could be used to
distinguish subclasses of CFS [35].
The two TPH2 SNPs associating with somatic symptoms
are different SNPs to those which showed association with
pain outcomes in our previous study [23], however, they lie
within the same haplotype block suggesting that variation in
this region of the gene may be important in susceptibility to
both somatization and pain. The same can be said of the
findings for SERPINA6 and HTR2A. For both genes,
multiple SNPs which were associated with somatic symp-
toms here were previously associated with CWP and/or the
number of pain sites reported e.g. an association of an
increase in the number of somatic symptoms co-occurs with
an increased risk for CWP and/or an increase in the number
of pain sites reported.
A major limitation of this study is that the data on somatic
symptoms was collected via a postal survey so we were
unable to assess whether there was any underlying
pathology, which might account for the bodily symptoms
reported. The somatic symptoms checklist was originally
validated as a screening test for somatization disorder [28]
and we have previously shown it to be a robust outcome
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baseline phase of the EPIFUND study to assess somatic
symptoms. A Somatic Symptoms Checklist score of 3 or
more (of 7 items) indicates probable somatization disorder
[28] and we found that 18% of our population scored 2 or
more on our brief (5 item) questionnaire. This suggest that
the participants in our study would correspond approximate-
ly to the populations studied by Barsky and Kroenke [39,40],
who used a self-administered questionnaire (PHQ-15) to
detect probable somatization without measuring whether
symptoms were explained by underlying organic disease or
not . However, in the analysis reported here, a count of the
number of somatic symptoms was used as the outcome of
interest. This approach allows all the available data to be
used which increases the statistical power of the study and
avoids using arbitrary cut-offs.
The associations reported here have modest effect sizes
and significance and may represent false positives as a
result of multiple testing. In order to correct for this we
used matrix spectral decomposition methodology proposed
by Li and Ji [41]. This method determines the number of
independent tests (n=123), accounting for LD between
SNPs, resulting in a p-value cut off of P=.0004. None of
our results reach this level of significance; however, this
approach may be too stringent and result in false negatives
if applied. Independent replication of our findings in other
large cohorts is essential to determine whether the observed
associations are false positives or true susceptibility loci for
somatization. Future studies should seek to validate these
findings but also to use different measures of somatization
such as the PHQ15 to determine the validity of the different
measures in genetic studies.
In addition this study only investigated a small number of
candidate genes. As the pathophysiology of somatization is
poorly understood, a large-scale genome-wide association
study would be a more appropriate method to identify genes
involved in somatization and to identify genes which are
shared between and unique to functional somatic syndromes.
A further limitation of this study is that ethnicity was not
determined; however, subjects were recruited from geo-
graphic areas that are predominantly white Caucasian. In
view of these limitations this should be regarded as a
preliminary report but as the first of its kind it makes an
important contribution.
In conclusion, we report associations between somatic
symptoms and genetic variation in two neuroendocrine
systems; the serotoninergic system and HPA axis. Our
findings do not appear to be explained by co-morbid
symptoms of depression or anxiety, which correlate with a
high number of bodily symptoms [42]. Replication of these
findings in large independent cohorts is required to
determine if the reported associations are valid. Our findings
are in keeping with results from our previous genetic
association studies of pain which adds weight to the body of
evidence which suggests that there is a shared genetic
component to functional somatic syndromes.Acknowledgments
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